Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2014

View Archived Issues

TaiGen Biotechnology presents phase III data for oral nemonoxacin

Clinical efficacy and safety of a novel antiretroviral drug for HIV infection

Neurocrine Biosciences begins trial of NBI-98854 in Tourette syndrome

Sorrento Therapeutics outlicenses Chinese rights to anti-PD-L1 antibody

Novartis and BMS collaborate on trials of anticancer immunotherapy combinations

DecImmune Therapeutics awarded SBIR grant to support DeciMab studies

Oryzon Genomics patents novel DDR1 antibodies for cancer

Researchers at Agios Pharmaceuticals patent novel agents for cancer and anemia

Novel agents investigated for fibrosis

Galapagos describes discovery of FFA2 antagonist in development for ulcerative colitis

Actavis and Durata Therapeutics enter merger agreement

Cell Cure Neurosciences files IND with the FDA for OpRegen

New PDE10A inhibitors patented by Merck & Co.

BMS and MD Anderson Cancer Center form immuno-oncology collaboration

Alcobra reports topline results from phase III study of metadoxine in adults with ADHD

Canadian group synthesizes novel PCSK9 inhibitors for LDL-C

Sunesis Pharmaceuticals reports data from pivotal phase III VALOR trial

Chimerix confirms emergency IND application for brincidofovir for Ebola

Capricor Therapeutics to advance CAP-1002 for Duchenne muscular dystrophy

Early clinical results for KRN-23 as potential treatment of X-linked hypophosphatemia

Perosphere signs new trial agreement with Daiichi Sankyo to study PER-977

Medac Pharma launches Rasuvo in U.S.

Acacia Pharma reports phase III data for APD-421 in post-operative nausea and vomiting

FDA expands approval for Eylea Injection in treating macular edema following retinal vein occlusion

Novel selective prostanoid EP2 receptor agonist shows promise in preclinical studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...